- Home
- LOCO vs ATYR Comparison
LOCO vs ATYR Comparison
Compare LOCO & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOCO
- ATYR
- Stock Information
- Founded
- LOCO 1980
- ATYR 2005
- Country
- LOCO United States
- ATYR United States
- Employees
- LOCO N/A
- ATYR N/A
- Industry
- LOCO Restaurants
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LOCO Consumer Discretionary
- ATYR Health Care
- Exchange
- LOCO Nasdaq
- ATYR Nasdaq
- Market Cap
- LOCO 327.1M
- ATYR 330.7M
- IPO Year
- LOCO 2014
- ATYR 2015
- Fundamental
- Price
- LOCO $10.17
- ATYR $3.87
- Analyst Decision
- LOCO Buy
- ATYR Strong Buy
- Analyst Count
- LOCO 3
- ATYR 6
- Target Price
- LOCO $15.50
- ATYR $18.60
- AVG Volume (30 Days)
- LOCO 319.6K
- ATYR 2.1M
- Earning Date
- LOCO 03-06-2025
- ATYR 03-13-2025
- Dividend Yield
- LOCO N/A
- ATYR N/A
- EPS Growth
- LOCO 16.22
- ATYR N/A
- EPS
- LOCO 0.86
- ATYR N/A
- Revenue
- LOCO $473,008,000.00
- ATYR $235,000.00
- Revenue This Year
- LOCO $6.09
- ATYR $1,387.23
- Revenue Next Year
- LOCO $1.28
- ATYR $873.22
- P/E Ratio
- LOCO $11.81
- ATYR N/A
- Revenue Growth
- LOCO 0.93
- ATYR N/A
- 52 Week Low
- LOCO $8.17
- ATYR $1.42
- 52 Week High
- LOCO $14.25
- ATYR $4.66
- Technical
- Relative Strength Index (RSI)
- LOCO 33.11
- ATYR 54.43
- Support Level
- LOCO $9.81
- ATYR $2.98
- Resistance Level
- LOCO $10.40
- ATYR $4.32
- Average True Range (ATR)
- LOCO 0.48
- ATYR 0.41
- MACD
- LOCO -0.07
- ATYR 0.06
- Stochastic Oscillator
- LOCO 20.45
- ATYR 72.14
About LOCO El Pollo Loco Holdings Inc.
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.